{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T22:06:51Z","timestamp":1791410811927,"version":"4.3.3"},"reference-count":20,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T00:00:00Z","timestamp":1740614400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100013220","name":"Ultragenyx Pharmaceutical Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013220","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lipidjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Lipidology"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.jacl.2025.02.012","type":"journal-article","created":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:21:46Z","timestamp":1740108106000},"page":"689-694","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Safety and effectiveness of evinacumab in an infant with homozygous familial hypercholesterolemia: A new renaissance for the very young?"],"prefix":"10.1016","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0756-3773","authenticated-orcid":false,"given":"Elena","family":"Fornari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Stefanutti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Mancioppi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald F.","family":"Watts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Livia","family":"Pisciotta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2631-9330","authenticated-orcid":false,"given":"Anita","family":"Morandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3563-4404","authenticated-orcid":false,"given":"Claudio","family":"Maffeis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacl.2025.02.012_bib0001","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.atherosclerosis.2019.08.014","article-title":"2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"290","author":"Mach","year":"2019","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacl.2025.02.012_bib0002","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1093\/eurheartj\/ehu274","article-title":"Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the consensus panel on familial hypercholesterolaemia of the European Atherosclerosis Society","volume":"35","author":"Cuchel","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2025.02.012_bib0003","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2020.572176","article-title":"Genetic and clinical characteristics of patients with homozygous and compound heterozygous familial hypercholesterolemia from three different populations: case series","volume":"11","author":"Marusic","year":"2020","journal-title":"Front Genet"},{"issue":"Suppl 5","key":"10.1016\/j.jacl.2025.02.012_bib0004","first-page":"S213","volume":"128","author":"de Jesus","year":"2011","journal-title":"Pediatrics"},{"key":"10.1016\/j.jacl.2025.02.012_bib0005","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1093\/eurheartj\/ehu058","article-title":"Homozygous autosomal dominant hypercholesterolaemia in The Netherlands: prevalence, genotype-phenotype relationship, and clinical outcome","volume":"36","author":"Sjouke","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2025.02.012_bib0006","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1093\/eurheartj\/ehad197","article-title":"2023 update on European Atherosclerosis Society consensus statement on homozygous familial hypercholesterolaemia: new treatments and clinical guidance","volume":"44","author":"Cuchel","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2025.02.012_bib0007","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1001\/jamacardio.2019.5173","article-title":"Reducing the clinical and public health burden of familial hypercholesterolemia: a global call to action","volume":"5","author":"Wilemon","year":"2020","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacl.2025.02.012_bib0008","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/s41569-023-00892-0","article-title":"International Atherosclerosis Society guidance for implementing best practice in the care of familial hypercholesterolaemia","volume":"20","author":"Watts","year":"2023","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.jacl.2025.02.012_bib0009","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1080\/080352501750258793","article-title":"Low-density lipoprotein apheresis in a patient aged 3.5 years","volume":"90","author":"Stefanutti","year":"2001","journal-title":"Acta Paediatr"},{"key":"10.1016\/j.jacl.2025.02.012_bib0010","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1111\/j.1525-1594.1997.tb00453.x","article-title":"LDL apheresis in a homozygous familial hypercholesterolemic child aged 4.5","volume":"21","author":"Stefanutti","year":"1997","journal-title":"Artif Organs"},{"key":"10.1016\/j.jacl.2025.02.012_bib0011","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1080\/17512433.2022.2047934","article-title":"Evinacumab for the treatment of homozygous familial hypercholesterolemia","volume":"15","author":"Gao","year":"2022","journal-title":"Expert Rev Clin Pharmacol"},{"key":"10.1016\/j.jacl.2025.02.012_bib0012","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1161\/CIRCULATIONAHA.123.065529","article-title":"Evinacumab for pediatric patients with homozygous familial hypercholesterolemia","volume":"149","author":"Wiegman","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2025.02.012_bib0013","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa2004215","article-title":"Evinacumab for homozygous familial hypercholesterolemia","volume":"383","author":"Raal","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2025.02.012_bib0014","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehae325","article-title":"Evinacumab in homozygous familial hypercholesterolaemia: long-term safety and efficacy","author":"Gaudet","year":"2024","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2025.02.012_bib0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.atherosclerosissup.2017.07.003","article-title":"The study of familial hypercholesterolemia in Italy: a narrative review","volume":"29","author":"Bertolini","year":"2017","journal-title":"Atheroscler Suppl"},{"key":"10.1016\/j.jacl.2025.02.012_bib0016","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/j.jacl.2016.04.006","article-title":"Clinical and molecular characteristics of homozygous familial hypercholesterolemia patients: insights from SAFEHEART registry","volume":"10","author":"Alonso","year":"2016","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2025.02.012_bib0017","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.atherosclerosis.2013.01.007","article-title":"Spectrum of mutations and phenotypic expression in patients with autosomal dominant hypercholesterolemia identified in Italy","volume":"227","author":"Bertolini","year":"2013","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacl.2025.02.012_bib0018","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/j.jacc.2018.05.044","article-title":"Clinical genetic testing for familial hypercholesterolemia: JACC Scientific Expert Panel","volume":"72","author":"Sturm","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2025.02.012_bib0019","first-page":"15","article-title":"Long-term efficacy and safety of evinacumab in patients with homozygous familial hypercholesterolemia: real-world clinical experience","author":"Stefanutti","year":"2022","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.jacl.2025.02.012_bib0020","doi-asserted-by":"crossref","first-page":"e817","DOI":"10.1016\/j.jacl.2024.05.006","article-title":"Real-world experience of long-term efficacy and safety of evinacumab in patients with homozygous familial hypercholesterolemia treated and not treating with lipoprotein apheresis","volume":"18","author":"Stefanutti","year":"2024","journal-title":"J Clin Lipidol J Clin Lipidol"}],"container-title":["Journal of Clinical Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287425000352?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287425000352?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T00:29:51Z","timestamp":1762561791000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1933287425000352"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":20,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S1933287425000352"],"URL":"https:\/\/doi.org\/10.1016\/j.jacl.2025.02.012","relation":{},"ISSN":["1933-2874"],"issn-type":[{"value":"1933-2874","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and effectiveness of evinacumab in an infant with homozygous familial hypercholesterolemia: A new renaissance for the very young?","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Lipidology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacl.2025.02.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 National Lipid Association.","name":"copyright","label":"Copyright"}]}}